Drug Trial Radar · NCT07781644
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
474
Planned (sponsor's estimate)
Start
Nov 11, 2026
Primary completion
Dec 15, 2028
Study completion Apr 15, 2032
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of RO7568282 compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Conditions
- Parkinson's Disease
Interventions
RO7568282Drug
RO7568282 will be administered as per the schedule specified in the protocol.
PlaceboDrug
Placebo will be administered as per the schedule specified in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to a Confirmed Motor Progression Event From the Randomization Date, as Measured by the MDS-UPDRS Part III ScoreTime frame: Up to at least Week 104
Locations
6 sites in 5 countries. Site status is shown where the registry gives one.
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida · Recruiting
Huashan Hospital, Fudan University
Shanghai, China · Recruiting
Cork University Hospital
Cork, Ireland · Recruiting
Centrum Medyczne NeuroProtect
Warsaw, Poland · Recruiting
Ninewells Hospital, Dundee- Scotland
Dundee, United Kingdom · Recruiting
Royal London Hospital
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.